Director, Medical Information

About Summit:

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Position Overview

The Director, Medical Information (MI) is a strategic leader responsible for building, scaling, and overseeing the MI function to ensure launch readiness and ongoing scientific excellence. This role will architect the full MI infrastructure—including systems, processes, governance, and content strategy—to support the company’s first commercial launch and future portfolio expansion.

A critical component of this role is leading to the end-to-end development and maintenance of MI capabilities that enable swift onboarding, integration, and operational readiness of the MI call center vendor , ensuring seamless, compliant, and highquality interactions with healthcare professionals, patients, and internal stakeholders.

The Director will collaborate cross‑functionally with Medical Affairs, Regulatory, Safety, Clinical Development, Clinical Operations, Compliance, and Commercial partners to ensure MI is tightly aligned with scientific, regulatory, and business needs. This is a highly visible role requiring scientific depth, operational excellence, and the ability to build new capabilities in a fast‑paced environment.

Key Responsibilities:

MI Strategy & Infrastructure Development

Lead and implement the design and build‑out of the MI infrastructure (i.e., MI Call Center), ensuring scalability, compliance, and readiness for US launch.

Assist in developing the MI operating model, including workflows, governance, content strategy, and cross‑functional interfaces, both in the USA and globally

Recruit, develop, and mentor MI personnel and establish organizational capabilities to support portfolio growth.

Evaluate generative AI, knowledge-management systems, chatbot solutions, and automation opportunities and develop the long-term digital MI roadmap.

Serve as the internal expert on MI regulations, industry standards, and best practices.

Call Center Vendor Management & Launch Readiness

Develop external (Call Center-specific) and internal (Summit-specific) MI SOPs, work instructions, training materials, and quality monitoring processes to ensure consistent, compliant, and high‑quality responses.

Ensure the call center is fully prepared for launch, including training, content availability, escalation pathways, and performance metrics.

Proactively manage call center/contractors responsible for responding to MIRs (including escalations from the call center) from Health Care Providers

Monitor vendor performance, quality, and compliance; implement corrective actions and continuous improvement initiatives.

Ensure readiness and adherence to internal and external audits are always maintained.

Scientific Content Leadership

Oversee the development, review, and approval of Standard Response Letters (SRLs), Custom Responses (CRs), Frequently Asked Questions (FAQs), and other MI scientific materials.

Ensure all MI content is scientifically rigorous, fair‑balanced, and aligned with evolving data, labeling, and safety information.

Lead regular advanced literature evaluation and data synthesis to support MI content and scientific responses.

Leverage technology and innovation to optimize the delivery of MI, including the use of digital platforms and AI tools.

Cross‑Functional Collaboration

Partner with Regulatory, Safety, Clinical Development, Compliance, and Medical Directors to ensure MI content reflects the most current scientific and safety information.

Assist with the development and creation of the AMCP dossiers (unapproved and approved use) in collaboration with senior MI personnel, HEOR lead, Market Access, Medical, Legal, Regulatory.

Develop data submission packages to key oncology guidelines and clinical pathways in collaboration with senior MI personnel, medical directors, HEOR lead and Marker Access.

Partner with the Head of the HEOR and the publications lead to develop NCCN and pathways submission plans.

Collaborate with Medical Affairs and Commercial teams to provide oversight for US and European conferences with activities including medical booths, logistics, materials, and staffing.

Provide insight into scientific communications planning (e.g, publications gap analysis) and internal training.

Serve as a key contributor to launch readiness planning and cross‑functional medical governance.

Insights, Metrics & Reporting

Establish and manage MI dashboards to track inquiry trends, operational performance, and scientific insights.

Contribute to the development of the MI annual and multi-year strategic and tactical plans including overall strategy and objectives.

Analyze and synthesize MI insights to inform Medical Affairs strategy, evidence generation, and cross‑functional decision‑making.

Present MI insights and operational updates to Medical Affairs leadership and cross‑functional partners. Keep abreast of trends and developments in MI and regulatory requirements and adapting strategies as needed

Qualifications:

Education

Doctoral degree in a health science discipline (PharmD, PhD, MD, or equivalent) required.

Oncology experience strongly preferred.

Experience

8+ years of MI experience in the pharmaceutical/biotech industry, with increasing leadership responsibility.

Demonstrated experience building or scaling MI systems, processes, or launch‑readiness capabilities.

Proven success overseeing MI call‑center vendors, including onboarding, training, and quality oversight.

Strong understanding of drug development, regulatory requirements, and medical affairs operations.

Experience supporting at least one US product launch preferred; first‑launch biotech experience a plus.

Skills & Competencies

Exceptional written and verbal communication skills with the ability to translate complex scientific data into clear, balanced information.

Strong leadership presence with the ability to influence across functions and manage external partners.

Highly organized, detail‑oriented, and able to manage multiple priori